Background The high activity antiretroviral therapy (HAART) should be efficient, safe and facilitate patient adherence.

Purpose To analyse immunovirological effectiveness, viral load (VL) and CD4 cells, safety (lipid profile) and adherence to 24 weeks of therapy change to emtricitabine/rilpivirine/tenofovir (FTC/RPV/TDF) from a previous HAART option.

Material and methods Observational and retrospective multicentre study. Included were all patients who switched to FTC/RPV/TDF during 2014 and continued with the new treatment for 24 weeks.

HAART schemes previous to the change were identified, and the results analysed for VL, CD4 cells and lipid profile (total cholesterol (TC), high density lipoprotein (HDL), low density lipoprotein (LDL) and triglyceride levels (TG)). Previous HAART was grouped by therapeutic scheme: 2NRTI+1NNRTI, 2NRTI+1PI and 2NRTI+1 integrase inhibitor. The results were analysed globally and by subgroups (according to previous HAART) at baseline and at 24 weeks.

We evaluated adherence pre and post-change, using records of dispensing (%adherence=total units dispensed/total units planned).

Results We included 73 patients (54 men and 19 women) with an average age of 45 years.

HAART schemes identified before the change: 44 patients 2NRTI+1NNRTI, 26 patients 2NRTI+1PI and 3 patients 2NRTI+1Integrase Inhibitor.

58 adherent patients and 15 non-adherent patients were detected, moreover 59 patients had negative VL and 14 positive VL. Following the change, adherence increased 18% (71 adherent and only 2 non-adherent) and VL became negative in all patients (except in the 2 non-adherent).

Effectiveness and lipid profile results analysed globally and subgroups at baseline and at 24 weeks are shown in table 1.

Conclusion

1. The change to FTC/RPV/TDF improved adherence to treatment.

2. At 24 weeks of switching to FTC/RPV/TDF the patients showed an excellent lipid profile and had good inmunovirological control.

References and/or Acknowledgements Cohen C, et al. Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials

No conflict of interest.